Am Regent Drug Patent Portfolio
Am Regent owns 5 orange book drugs protected by 17 US patents with Dexferrum having the least patent protection, holding only 1 patent. And Injectafer with maximum patent protection, holding 11 patents. Given below is the list of Am Regent's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11786548 | Trace element compositions, methods of making and use | 01 Jul, 2041 | Active |
| US11975022 | Trace element compositions, methods of making and use | 01 Jul, 2041 | Active |
| US11998565 | Trace element compositions, methods of making and use | 01 Jul, 2041 | Active |
| US12150956 | Trace element compositions, methods of making and use | 01 Jul, 2041 | Active |
| US12150957 | Trace element compositions, methods of making and use | 01 Jul, 2041 | Active |
| US7754702 | Methods and compositions for administration of iron | 15 Feb, 2028 | Active |
| US11364260 | Methods and compositions for administration of iron | 08 Jan, 2027 | Active |
| US11433091 | Methods and compositions for administration of iron | 08 Jan, 2027 | Active |
| US11478502 | Methods and compositions for administration of iron | 08 Jan, 2027 | Active |
| US8895612 | Methods and compositions for administration of iron | 08 Jan, 2027 | Active |
| US7612109 | Water-soluble iron-carbohydrate complexes, production thereof, and medicaments containing said complexes | 05 Feb, 2026 | Active |
| US10519252 | Aqueous iron carbohydrate complexes, their production and medicaments containing them | 20 Oct, 2023 | Expired |
| US11123321 | Aqueous iron carbohydrate complexes, their production and medicaments containing them | 20 Oct, 2023 | Expired |
| US11291645 | Aqueous iron carbohydrate complexes, their production and medicaments containing them | 20 Oct, 2023 | Expired |
| US11590097 | Aqueous iron carbohydrate complexes, their production and medicaments containing them | 20 Oct, 2023 | Expired |
| US9376505 | Aqueous iron carbohydrate complexes, their production and medicaments containing them | 20 Oct, 2023 | Expired |
| US5624668 | Iron dextran formulations | 29 Sep, 2015 | Expired |
Latest Legal Activities on Am Regent's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Am Regent.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Mail Patent eGrant Notification | 07 May, 2024 | US11975022 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 07 May, 2024 | US11975022 |
|
Email Notification
Critical
| 07 May, 2024 | US11975022 |
|
Recordation of Patent Grant Mailed
Critical
| 07 May, 2024 | US11975022 |
| Patent eGrant Notification | 07 May, 2024 | US11975022 |
| Recordation of Patent eGrant | 07 May, 2024 | US11975022 |
|
Email Notification
Critical
| 18 Apr, 2024 | US11975022 |
|
Issue Notification Mailed
Critical
| 17 Apr, 2024 | US11975022 |
| Dispatch to FDC | 02 Apr, 2024 | US11975022 |
|
Application Is Considered Ready for Issue
Critical
| 02 Apr, 2024 | US11975022 |
|
Issue Fee Payment Received
Critical
| 28 Mar, 2024 | US11975022 |
|
Issue Fee Payment Verified
Critical
| 28 Mar, 2024 | US11975022 |
| Response to Reasons for Allowance | 28 Mar, 2024 | US11975022 |
|
Email Notification
Critical
| 22 Mar, 2024 | US11975022 |
| Mailing Corrected Notice of Allowability | 22 Mar, 2024 | US11975022 |
Am Regent's Drug Patent Litigations
Am Regent's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jun 24, 2015, against patent number US8895612. The petitioner Pharmacosmos A/S, challenged the validity of this patent, with Luitpold Pharmaceuticals, Inc. as the respondent. Click below to track the latest information on how companies are challenging Am Regent's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US7754702 | June, 2015 |
Final Written Decision
(04 Jan, 2017)
| Luitpold Pharmaceuticals, Inc. | Pharmacosmos A/S |
| US8895612 | June, 2015 |
Terminated-Denied
(08 Jan, 2016)
| Luitpold Pharmaceuticals, Inc. | Pharmacosmos A/S |
Am Regent Drug Patents' Oppositions Filed in EPO
Am Regent drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Feb 27, 2013, by Kernebeck Patentanwalts Gmbh. This opposition was filed on patent number EP10194332A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP07716309A | Apr, 2017 | STADA Arzneimittel AG | Granted and Under Opposition |
| EP07716309A | Apr, 2017 | Generics [U.K.] Limited | Granted and Under Opposition |
| EP07716309A | Apr, 2017 | Taylor Wessing LLP | Granted and Under Opposition |
| EP07716309A | Apr, 2017 | HGF Limited | Granted and Under Opposition |
| EP07716309A | Apr, 2017 | TEVA PHARMACEUTICAL INDUSTRIES, LTD. | Granted and Under Opposition |
| EP07716309A | Apr, 2017 | Pharmacosmos Holding A/S | Granted and Under Opposition |
| EP07716309A | Apr, 2017 | Hoffmann Eitle | Granted and Under Opposition |
| EP10194332A | Feb, 2013 | Kernebeck Patentanwalts GmbH | Opposition rejected |
Am Regent's Family Patents
Am Regent Drug List
Given below is the complete list of Am Regent's drugs and the patents protecting them.
1. Dexferrum
Dexferrum is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5624668 | Iron dextran formulations |
29 Sep, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Dexferrum's drug page
2. Injectafer
Injectafer is protected by 11 patents, out of which 5 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7754702 | Methods and compositions for administration of iron |
15 Feb, 2028
(2 years from now)
| Active |
| US11364260 | Methods and compositions for administration of iron |
08 Jan, 2027
(1 year, 7 months from now)
| Active |
| US11433091 | Methods and compositions for administration of iron |
08 Jan, 2027
(1 year, 7 months from now)
| Active |
| US11478502 | Methods and compositions for administration of iron |
08 Jan, 2027
(1 year, 7 months from now)
| Active |
| US8895612 | Methods and compositions for administration of iron |
08 Jan, 2027
(1 year, 7 months from now)
| Active |
| US7612109 | Water-soluble iron-carbohydrate complexes, production thereof, and medicaments containing said complexes |
05 Feb, 2026
(8 months from now)
| Active |
| US10519252 | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
20 Oct, 2023
(1 year, 6 months ago)
| Expired |
| US11123321 | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
20 Oct, 2023
(1 year, 6 months ago)
| Expired |
| US11291645 | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
20 Oct, 2023
(1 year, 6 months ago)
| Expired |
| US11590097 | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
20 Oct, 2023
(1 year, 6 months ago)
| Expired |
| US9376505 | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
20 Oct, 2023
(1 year, 6 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Injectafer's drug page
3. Multrys
Multrys is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11786548 | Trace element compositions, methods of making and use |
01 Jul, 2041
(16 years from now)
| Active |
| US11975022 | Trace element compositions, methods of making and use |
01 Jul, 2041
(16 years from now)
| Active |
| US11998565 | Trace element compositions, methods of making and use |
01 Jul, 2041
(16 years from now)
| Active |
| US12150956 | Trace element compositions, methods of making and use |
01 Jul, 2041
(16 years from now)
| Active |
| US12150957 | Trace element compositions, methods of making and use |
01 Jul, 2041
(16 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Multrys's drug page
4. Selenious Acid
Selenious Acid is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11998565 | Trace element compositions, methods of making and use |
01 Jul, 2041
(16 years from now)
| Active |
| US12150957 | Trace element compositions, methods of making and use |
01 Jul, 2041
(16 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Selenious Acid's drug page
5. Tralement
Tralement is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11786548 | Trace element compositions, methods of making and use |
01 Jul, 2041
(16 years from now)
| Active |
| US11975022 | Trace element compositions, methods of making and use |
01 Jul, 2041
(16 years from now)
| Active |
| US11998565 | Trace element compositions, methods of making and use |
01 Jul, 2041
(16 years from now)
| Active |
| US12150956 | Trace element compositions, methods of making and use |
01 Jul, 2041
(16 years from now)
| Active |
| US12150957 | Trace element compositions, methods of making and use |
01 Jul, 2041
(16 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tralement's drug page